Patterns of use and duration taking anti-TNF medications. Data are median days (75th–25th percentiles).
| 2000, n = 695 | 2001, n = 1126 | 2002, n = 1183 | 2003, n = 2881 | 2004, n = 2698 | p | |
|---|---|---|---|---|---|---|
| Etanercept | ||||||
| Time on 1st TNF (total cohort) | 560 (899.5–224) | 410 (680–213) | 341 (752–154) | 436 (656.5–166.5) | 212 (335–89) | < 0.0001 |
| Time to switch | 381 (635.5–190) | 244 (553–68) | 156 (370–93.5) | 156 (307–68) | 113 (167–40) | < 0.0001 |
| Infliximab | ||||||
| Time on 1st TNF (total cohort) | 483 (793–209) | 469 (770–240) | 343 (858.5–197) | 581 (775–217) | 328 (455–184) | < 0.0001 |
| Time to switch | 253 (631–103) | 482 (723–186) | 244 (395–150) | 203 (341–88) | 154 (239–98) | 0.02 |
| Adalimumab | ||||||
| Time on 1st TNF (total cohort) | * | * | * | 371 (670–131) | 280 (397.5–148) | < 0.0001 |
| Time to switch | * | * | * | 136 (266–43) | 97 (197–62) | 0.02 |